Avenue Therapeutics, Inc. (ATXI) stock
ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.43+0.00 (0.00%)
Close on Oct 16, 2026Market cap $1.42MP/E –Yield –
Avenue Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Avenue Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$2.90M. For fiscal 2025 it was -$3.08M. The highest annual figure on record is -$2.38M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.08M | – |
| FY2024 | Dec 31, 2024 | -$11.28M | – |
| FY2023 | Dec 31, 2023 | -$14.54M | – |
| FY2022 | Dec 31, 2022 | -$8.04M | – |
| FY2021 | Dec 31, 2021 | -$3.74M | – |
| FY2020 | Dec 31, 2020 | -$5.21M | – |
| FY2019 | Dec 31, 2019 | -$26.27M | – |
| FY2018 | Dec 31, 2018 | -$21.82M | – |
| FY2017 | Dec 31, 2017 | -$11.42M | – |
| FY2016 | Dec 31, 2016 | -$2.38M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$707.00K | -338.0% |
| Q1 FY2026 | Mar 31, 2026 | -$714.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$752.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$724.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $297.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.60M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.16M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.07M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.43M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$663.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$605.00K | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$914.00K | – |
| Q3 FY2021 | Sep 30, 2021 | -$872.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$951.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.00M | – |
| Q4 FY2020 | Dec 31, 2020 | -$999.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.90M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.27M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.47M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.11M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.36M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.10M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.61M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.68M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.43M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.33M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.85M | – |
| Q4 FY2016 | Dec 31, 2016 | -$516.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$383.00K | – |
| Q2 FY2016 | Jun 30, 2016 | -$638.00K | – |
See a number that looks wrong?